期刊
TRANSLATIONAL RESEARCH
卷 201, 期 -, 页码 26-39出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2018.08.002
关键词
-
资金
- NIH [K08 DK102542, R01 AI129959, R01 DK110077, UM1-DK100865]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI129959] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK102542, R01DK110077] Funding Source: NIH RePORTER
Patients with systemic lupus erythematosus frequently develop lupus nephritis (LN), a condition that can lead to end-stage kidney disease. Multiple serum and urine biomarkers for LN have been proposed in recent years, yet none have become incorporated into clinical use. The majority of studies have been single center with significant variability in cohorts, assays, and sample storage, leading to inconclusive results. It has become clear that no single biomarker is likely to be sufficient to diagnose LN, identify flares, and define the response to therapy and prognosis. A more likely scenario is a panel of urine, serum, tissue, and genetic biomarkers. In this review, we summarize traditional and novel biomarkers and discuss how they may be utilized in order to bring precision medicine to clinical practice in LN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据